Given that paclitaxel exhibited a greater microtubule-stabilizing effect in ARIH1-deficient cells, we hypothesized that breast cancer cells lacking ARIH1 would demonstrate increased sensitivity and responsiveness to the cytotoxic effects of paclitaxel. This evidence concerns the gene ARIH1 and breast carcinoma.